Drug Combination Details
| General Information of the Combination (ID: C44375) | |||||
|---|---|---|---|---|---|
| Name | Schisandrin A NP Info | + | Deoxynivalenol Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Indeterminate colitis
[ICD-11: DD72]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Sch A decreased the DON-induced cyclooxygenase-2 expression and prostaglandin E2 production and pro-inflammatory cytokine interleukin 8 expression and secretion. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Schisandrin A protects intestinal epithelial cells from deoxynivalenol-induced cytotoxicity, oxidative damage and inflammation. Sci Rep. 2019 Dec 16;9(1):19173. | |||
